A citation-based method for searching scientific literature

Barbara M Norquist, Maria I Harrell, Mark F Brady, Tom Walsh, Ming K Lee, Suleyman Gulsuner, Sarah S Bernards, Silvia Casadei, Qian Yi, Robert A Burger, John K Chan, Susan A Davidson, Robert S Mannel, Paul A DiSilvestro, Heather A Lankes, Nilsa C Ramirez, Mary Claire King, Elizabeth M Swisher, Michael J Birrer. JAMA Oncol 2016
Times Cited: 331







List of co-cited articles
905 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Underdiagnosis of Hereditary Breast and Ovarian Cancer in Medicare Patients: Genetic Testing Criteria Miss the Mark.
Shan Yang, Jennifer E Axilbund, Erin O'Leary, Scott T Michalski, Robbie Evans, Stephen E Lincoln, Edward D Esplin, Robert L Nussbaum. Ann Surg Oncol 2018
23
17

The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.
Ethan Cerami, Jianjiong Gao, Ugur Dogrusoz, Benjamin E Gross, Selcuk Onur Sumer, Bülent Arman Aksoy, Anders Jacobsen, Caitlin J Byrne, Michael L Heuer, Erik Larsson,[...]. Cancer Discov 2012
4

Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results.
Sharon E Plon, Diana M Eccles, Douglas Easton, William D Foulkes, Maurizio Genuardi, Marc S Greenblatt, Frans B L Hogervorst, Nicoline Hoogerbrugge, Amanda B Spurdle, Sean V Tavtigian. Hum Mutat 2008
536
4

Inherited DNA-Repair Defects in Colorectal Cancer.
Saud H AlDubayan, Marios Giannakis, Nathanael D Moore, G Celine Han, Brendan Reardon, Tsuyoshi Hamada, Xinmeng Jasmine Mu, Reiko Nishihara, Zhirong Qian, Li Liu,[...]. Am J Hum Genet 2018
44
9

PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2.
Fan Zhang, Qiang Fan, Keqin Ren, Paul R Andreassen. Mol Cancer Res 2009
178
4

PALB2 links BRCA1 and BRCA2 in the DNA-damage response.
Feng Zhang, Jianglin Ma, Jiaxue Wu, Lin Ye, Hong Cai, Bing Xia, Xiaochun Yu. Curr Biol 2009
321
4

PALB2 is an integral component of the BRCA complex required for homologous recombination repair.
Shirley M H Sy, Michael S Y Huen, Junjie Chen. Proc Natl Acad Sci U S A 2009
338
4

Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
Eric Pujade-Lauraine, Felix Hilpert, Béatrice Weber, Alexander Reuss, Andres Poveda, Gunnar Kristensen, Roberto Sorio, Ignace Vergote, Petronella Witteveen, Aristotelis Bamias,[...]. J Clin Oncol 2014
734
4

High grade serous ovarian carcinomas originate in the fallopian tube.
S Intidhar Labidi-Galy, Eniko Papp, Dorothy Hallberg, Noushin Niknafs, Vilmos Adleff, Michael Noe, Rohit Bhattacharya, Marian Novak, Siân Jones, Jillian Phallen,[...]. Nat Commun 2017
228
4

BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.
Kevin K Lin, Maria I Harrell, Amit M Oza, Ana Oaknin, Isabelle Ray-Coquard, Anna V Tinker, Elena Helman, Marc R Radke, Carmen Say, Lan-Thanh Vo,[...]. Cancer Discov 2019
89
4

Ovarian cancer.
Ursula A Matulonis, Anil K Sood, Lesley Fallowfield, Brooke E Howitt, Jalid Sehouli, Beth Y Karlan. Nat Rev Dis Primers 2016
277
4

PARP inhibitors: Synthetic lethality in the clinic.
Christopher J Lord, Alan Ashworth. Science 2017
779
4

Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment.
Allison W Kurian, Emily E Hare, Meredith A Mills, Kerry E Kingham, Lisa McPherson, Alice S Whittemore, Valerie McGuire, Uri Ladabaum, Yuya Kobayashi, Stephen E Lincoln,[...]. J Clin Oncol 2014
299
4

BRCA germline mutations in an unselected nationwide cohort of Chinese patients with ovarian cancer and healthy controls.
Ang Li, Rong Xie, Qihuan Zhi, Yixiao Deng, Yangming Wu, Weiwei Li, Lu Yang, Zinan Jiao, Jiaqi Luo, Yi Zi,[...]. Gynecol Oncol 2018
16
25


Cancer Risks for PMS2-Associated Lynch Syndrome.
Sanne W Ten Broeke, Heleen M van der Klift, Carli M J Tops, Stefan Aretz, Inge Bernstein, Daniel D Buchanan, Albert de la Chapelle, Gabriel Capella, Mark Clendenning, Christoph Engel,[...]. J Clin Oncol 2018
72
5

Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers.
Claudia Marchetti, Francesca De Felice, Innocenza Palaia, Giorgia Perniola, Angela Musella, Daniela Musio, Ludovico Muzii, Vincenzo Tombolini, Pierluigi Benedetti Panici. BMC Womens Health 2014
84
4

Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations.
Catherine A Shu, Malcolm C Pike, Anjali R Jotwani, Tara M Friebel, Robert A Soslow, Douglas A Levine, Katherine L Nathanson, Jason A Konner, Angela G Arnold, Faina Bogomolniy,[...]. JAMA Oncol 2016
107
4

Counselling framework for moderate-penetrance cancer-susceptibility mutations.
Nadine Tung, Susan M Domchek, Zsofia Stadler, Katherine L Nathanson, Fergus Couch, Judy E Garber, Kenneth Offit, Mark E Robson. Nat Rev Clin Oncol 2016
153
4

PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene.
Nazneen Rahman, Sheila Seal, Deborah Thompson, Patrick Kelly, Anthony Renwick, Anna Elliott, Sarah Reid, Katarina Spanova, Rita Barfoot, Tasnim Chagtai,[...]. Nat Genet 2007
642
4

Mutations in BRCA2 and PALB2 in male breast cancer cases from the United States.
Yuan Chun Ding, Linda Steele, Chih-Jen Kuan, Scott Greilac, Susan L Neuhausen. Breast Cancer Res Treat 2011
72
5

BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study.
David B Zhen, Kari G Rabe, Steven Gallinger, Sapna Syngal, Ann G Schwartz, Michael G Goggins, Ralph H Hruban, Michele L Cote, Robert R McWilliams, Nicholas J Roberts,[...]. Genet Med 2015
131
4

Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.
Willemien J van Driel, Simone N Koole, Karolina Sikorska, Jules H Schagen van Leeuwen, Henk W R Schreuder, Ralph H M Hermans, Ignace H J T de Hingh, Jacobus van der Velden, Henriëtte J Arts, Leon F A G Massuger,[...]. N Engl J Med 2018
453
4

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
Deborah K Armstrong, Brian Bundy, Lari Wenzel, Helen Q Huang, Rebecca Baergen, Shashikant Lele, Larry J Copeland, Joan L Walker, Robert A Burger. N Engl J Med 2006
4

Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
Sandro Pignata, Giovanni Scambia, Dionyssios Katsaros, Ciro Gallo, Eric Pujade-Lauraine, Sabino De Placido, Alessandra Bologna, Beatrice Weber, Francesco Raspagliesi, Pierluigi Benedetti Panici,[...]. Lancet Oncol 2014
200
4

Genetic Testing and Counseling Among Patients With Newly Diagnosed Breast Cancer .
Allison W Kurian, Kent A Griffith, Ann S Hamilton, Kevin C Ward, Monica Morrow, Steven J Katz, Reshma Jagsi. JAMA 2017
68
5

Germline pathogenic variants of 11 breast cancer genes in 7,051 Japanese patients and 11,241 controls.
Yukihide Momozawa, Yusuke Iwasaki, Michael T Parsons, Yoichiro Kamatani, Atsushi Takahashi, Chieko Tamura, Toyomasa Katagiri, Teruhiko Yoshida, Seigo Nakamura, Kokichi Sugano,[...]. Nat Commun 2018
49
8

Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.
Darren R Hodgson, Brian A Dougherty, Zhongwu Lai, Anitra Fielding, Lynda Grinsted, Stuart Spencer, Mark J O'Connor, Tony W Ho, Jane D Robertson, Jerry S Lanchbury,[...]. Br J Cancer 2018
67
5

Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
Jonathan A Ledermann, Philipp Harter, Charlie Gourley, Michael Friedlander, Ignace Vergote, Gordon Rustin, Clare Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra,[...]. Lancet Oncol 2016
229
4


Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation.
Joanne Kotsopoulos, Jacek Gronwald, Beth Karlan, Barry Rosen, Tomasz Huzarski, Pal Moller, Henry T Lynch, Christian F Singer, Leigha Senter, Susan L Neuhausen,[...]. Gynecol Oncol 2018
36
11

Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study.
Marline G Harmsen, Marieke Arts-de Jong, Nicoline Hoogerbrugge, Angela H E M Maas, Judith B Prins, Johan Bulten, Steven Teerenstra, Eddy M M Adang, Jurgen M J Piek, Helena C van Doorn,[...]. BMC Cancer 2015
54
7

Bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction: A pilot study in women with BRCA1/2 mutations.
Denise R Nebgen, Jean Hurteau, Laura L Holman, Andrea Bradford, Mark F Munsell, Beth R Soletsky, Charlotte C Sun, Gary B Chisholm, Karen H Lu. Gynecol Oncol 2018
27
14


Lifetime cancer risks in individuals with germline PTEN mutations.
Min-Han Tan, Jessica L Mester, Joanne Ngeow, Lisa A Rybicki, Mohammed S Orloff, Charis Eng. Clin Cancer Res 2012
415
4

Penetrance of ATM Gene Mutations in Breast Cancer: A Meta-Analysis of Different Measures of Risk.
Monica Marabelli, Su-Chun Cheng, Giovanni Parmigiani. Genet Epidemiol 2016
47
8

Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancer.
Nana Weber-Lassalle, Julika Borde, Konstantin Weber-Lassalle, Judit Horváth, Dieter Niederacher, Norbert Arnold, Silke Kaulfuß, Corinna Ernst, Victoria G Paul, Ellen Honisch,[...]. Breast Cancer Res 2019
14
28

CHEK2 is a multiorgan cancer susceptibility gene.
C Cybulski, B Górski, T Huzarski, B Masojć, M Mierzejewski, T Debniak, U Teodorczyk, T Byrski, J Gronwald, J Matyjasik,[...]. Am J Hum Genet 2004
309
4

BRCA1 and BRCA2: different roles in a common pathway of genome protection.
Rohini Roy, Jarin Chun, Simon N Powell. Nat Rev Cancer 2011
675
4

A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.
Y Miki, J Swensen, D Shattuck-Eidens, P A Futreal, K Harshman, S Tavtigian, Q Liu, C Cochran, L M Bennett, W Ding. Science 1994
4

Signatures of mutational processes in human cancer.
Ludmil B Alexandrov, Serena Nik-Zainal, David C Wedge, Samuel A J R Aparicio, Sam Behjati, Andrew V Biankin, Graham R Bignell, Niccolò Bolli, Ake Borg, Anne-Lise Børresen-Dale,[...]. Nature 2013
4

Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.
John R McLaughlin, Harvey A Risch, Jan Lubinski, Pal Moller, Parviz Ghadirian, Henry Lynch, Beth Karlan, David Fishman, Barry Rosen, Susan L Neuhausen,[...]. Lancet Oncol 2007
139
4

Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial.
Saundra S Buys, Edward Partridge, Amanda Black, Christine C Johnson, Lois Lamerato, Claudine Isaacs, Douglas J Reding, Robert T Greenlee, Lance A Yokochi, Bruce Kessel,[...]. JAMA 2011
706
4

Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers.
Janice S Kwon, Anna Tinker, Gary Pansegrau, Jessica McAlpine, Melissa Housty, Mary McCullum, C Blake Gilks. Obstet Gynecol 2013
102
4

Improving performance of multigene panels for genomic analysis of cancer predisposition.
Brian H Shirts, Silvia Casadei, Angela L Jacobson, Ming K Lee, Suleyman Gulsuner, Robin L Bennett, Margaret Miller, Sarah A Hall, Heather Hampel, Fuki M Hisama,[...]. Genet Med 2016
52
7

Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability.
Asad Umar, C Richard Boland, Jonathan P Terdiman, Sapna Syngal, Albert de la Chapelle, Josef Rüschoff, Richard Fishel, Noralane M Lindor, Lawrence J Burgart, Richard Hamelin,[...]. J Natl Cancer Inst 2004
4

Structural basis for recruitment of BRCA2 by PALB2.
Antony W Oliver, Sally Swift, Christopher J Lord, Alan Ashworth, Laurence H Pearl. EMBO Rep 2009
110
4

Enhancement of RAD51 recombinase activity by the tumor suppressor PALB2.
Eloïse Dray, Julia Etchin, Claudia Wiese, Dorina Saro, Gareth J Williams, Michal Hammel, Xiong Yu, Vitold E Galkin, Dongqing Liu, Miaw-Sheue Tsai,[...]. Nat Struct Mol Biol 2010
104
4

Opportunistic testing of BRCA1, BRCA2 and mismatch repair genes improves the yield of phenotype driven hereditary cancer gene panels.
Lídia Feliubadaló, Adrià López-Fernández, Marta Pineda, Orland Díez, Jesús Del Valle, Sara Gutiérrez-Enríquez, Alex Teulé, Sara González, Neda Stjepanovic, Mónica Salinas,[...]. Int J Cancer 2019
17
23

Cancer Statistics, 2017.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2017
4


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.